




Portuguese Society of
CARDIOLOGY

Revista Portuguesa de **Cardiologia**

Portuguese Journal of **Cardiology**

www.revportcardiol.org



CASE REPORT

Iatrogenic ventricular fibrillation in Wolff-Parkinson-White syndrome



Alzira Nunes^{a,*}, Ana Lebreiro^a, Manuel Campelo^{a,b}, Luís Adão^a, Maria Júlia Maciel^{a,b}

^a Serviço de Cardiologia, Centro Hospitalar Universitário de São João, Porto, Portugal

^b Faculdade de Medicina da Universidade do Porto, Porto, Portugal

Received 12 December 2018; accepted 9 June 2019

Available online 14 September 2022

KEYWORDS

Wolff-Parkinson-White;
Accessory pathway;
Pre-excited atrial fibrillation;
Ventricular fibrillation;
Atrioventricular nodal blockers;
Catheter ablation

Abstract Wolff-Parkinson-White (WPW) syndrome is the most common manifestation of ventricular pre-excitation syndrome and is mostly found in individuals with no structural heart disease. Although the risk of malignant arrhythmias is low, sudden cardiac death (SCD) as the first clinical manifestation of WPW syndrome is well documented, and atrial fibrillation (AF) with a rapid ventricular response is the main mechanism involved. Unfortunately, the signs of pre-excitation and arrhythmias are sometimes under-diagnosed and under-treated. We describe the case of a 31-year-old man who was admitted with an irregular wide complex tachycardia consistent with pre-excited AF, which was not promptly diagnosed, and who developed ventricular fibrillation (VF) after administration of atrioventricular (AV) nodal blockers, as a primary manifestation of WPW syndrome. Blocking the AV node in patients with pre-excited AF may increase the ventricular rate and potentially result in hemodynamic instability. Among patients with WPW syndrome who survive an episode of SCD, catheter ablation of the accessory pathway is the treatment of choice.

© 2022 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALAVRAS-CHAVE

Wolff-Parkinson-White;
Via acessória;
Fibrilação auricular pré-excitada;
Fibrilação ventricular;

Fibrilação ventricular iatrogénica na síndrome de Wolff-Parkinson-White

Resumo A síndrome de Wolff-Parkinson-White (WPW) é a manifestação mais comum da síndrome de pré-exitação ventricular e está presente maioritariamente em indivíduos sem cardiopatia estrutural. Embora o risco de arritmias malignas seja baixo, a morte súbita cardíaca (MSC) como primeira manifestação clínica da síndrome de WPW é uma ocorrência bem documentada e a fibrilação auricular (FA) com resposta ventricular rápida é o principal mecanismo envolvido. Infelizmente, às vezes, os sinais de pré-exitação e as arritmias são subdiagnosticados e subtratados. Descrevemos o caso de um homem de 31 anos admitido com uma taquicardia

* Corresponding author.

E-mail address: zira.nunes.2@gmail.com (A. Nunes).

Bloqueadores do nó auriculoventricular;
Ablação por cateter

irregular de complexos largos consistente com FA pré-excitada, não diagnosticada de imediato, que evoluiu para fibrilação ventricular (FV) após a administração de bloqueadores do nó auriculoventricular (AV), como manifestação inaugural da síndrome de WPW. O bloqueio do nó AV, em pacientes com FA pré-excitada, pode aumentar a frequência ventricular e potencialmente resultar em instabilidade hemodinâmica. Entre os pacientes com síndrome de WPW que sobrevivem a um episódio de MSC, a ablação por cateter de via acessória (VA) é o tratamento de escolha.

© 2022 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Wolff-Parkinson-White (WPW) syndrome refers to the association of manifest pre-excitation and symptoms due to reentrant arrhythmias. The risk of malignant arrhythmias is low but sudden cardiac death (SCD) may be the first manifestation of this condition.¹ More frequently, these patients suffer from atrioventricular reentrant tachycardia (AVRT) and/or pre-excited atrial fibrillation (AF) with rapid anterograde conduction through an accessory pathway (AP) that can deteriorate into ventricular fibrillation (VF).² Electrophysiological study (EPS) and radiofrequency ablation (RFA) of the AP is therefore recommended in symptomatic patients as it is a very effective treatment and can prevent a potentially fatal outcome.³

Case report

A 31-year-old man with no known cardiac disease, a family history of SCD in a paternal aunt and uncle in the 1950s, and a history of long-standing paroxysmal palpitations that resolved with vagal maneuvers (never documented on an electrocardiogram [ECG]), was admitted to the emergency department (ED) complaining of palpitations that persisted despite the usual Valsalva maneuvers. No medication or drug abuse was reported.

The patient was hemodynamically stable, with normal blood pressure (150/70 mmHg) and an irregular pulse approaching 200 bpm. The rest of the physical assessment was unremarkable, with no cardiac murmurs or signs of pulmonary edema. An ECG revealed an irregular wide complex tachycardia (Figure 1).

At the ED a decision was made to give intravenous adenosine (6+12+12 mg), followed by intravenous verapamil (2.5 mg). After the administration of these drugs, the




Figure 1 Electrocardiogram on admission showing wide QRS complex irregular tachycardia consistent with pre-excited AF.

patient developed VF which was reverted after two external defibrillator shocks (2×200 J, biphasic). A subsequent ECG showed a subtle pre-excitation pattern in the lateral leads, especially in V4-V5 (Figure 2). Laboratory parameters were normal and transthoracic echocardiography excluded structural heart disease.

The patient was then referred for an EPS and a left lateral AP was diagnosed, capable of anterograde and retrograde conduction. Orthodromic AVRT was easily induced with both ventricular and atrial stimulation (Figures 3 and 4). The anterograde refractory period of the AP was 240 ms. Ablation of this pathway (Figure 5) was then successfully performed under ventricular pacing, the retrograde conduction through the AP disappearing immediately after starting radiofrequency (<3 s). Anterograde conduction was also confirmed to be absent after stopping radiofrequency. The procedure was uneventful and the subsequent ECG showed normal sinus rhythm (Figure 6).

The patient was discharged home on the following day. One month after RFA he was asymptomatic with a normal ECG tracing and no tachyarrhythmias were documented during this period.

Discussion

Under physiological conditions, conduction from the atria to the ventricles occurs via the AV node and the His-Purkinje system. Patients with a pre-excitation syndrome have at least one AP that directly connects the atria and ventricles, thereby allowing electrical activity to bypass the AV node.




Figure 2 Shortened PR interval, delta wave and widened QRS complex indicative of Wolff-Parkinson-White pattern.




Figure 3 After programmed ventricular pacing, the extra-stimulus maintained eccentric and non-decremental ventriculoatrial conduction up to 220 ms, and it was at this time, when the atrioventricular node was outside the refractory period and available for anterograde conduction, that orthodromic atrioventricular reentrant tachycardia was induced (arrow).



Figure 4 During programmed atrial pacing, atrioventricular conduction was performed through the accessory pathway until its anterograde refractory period (<240 ms) was reached. The impulse then proceeded to the ventricle via the atrioventricular node, leaving the accessory pathway available for retrograde conduction, and atrioventricular reentrant tachycardia had started (arrow).

Tissue in the AP typically conducts electrical impulses more quickly than the AV node, resulting in earlier activation of the ventricles, and is responsible for the classic ECG findings of a shortened PR interval (<0.12 s), slurring and slow rise of the initial QRS complex, and widened QRS complex (>0.12 s).

The prevalence of a WPW pattern on the surface ECG is estimated at 0.13–0.25% in the general population, but the prevalence of WPW syndrome is substantially lower.⁴ Diagnosis of WPW syndrome requires typical ECG findings with a documented dysrhythmia.

The most frequently found dysrhythmias in patients with WPW are AVRT and AF. Fortunately, the incidence of SCD in patients with WPW syndrome is quite low, ranging from 0.1 to 0.39%.³ Predicting clinical outcome is one of the major




Figure 5 Ablation of a left lateral accessory pathway with criteria of success. Shortly (about 3 s) after the onset of ablation, the ventricular (stars) and atrial (arrows) signals separate, suggesting elimination of the accessory pathway, and conduction begins through the AV node.



Figure 6 Electrocardiogram performed after catheter ablation showing normal sinus rhythm, without evidence of pre-excitation.

issues in WPW patients and remains a considerable clinical challenge. Risk factors for potentially life-threatening arrhythmic events in WPW syndrome^{5,6} include a short AP refractory period (<250 ms) allowing a rapid ventricular response in AF, inducibility of tachyarrhythmia during EPS (AVRT and/or AF), short pre-excited RR interval during AF (<250 ms), multiple APs, male gender, age and syncope.

In patients with an AP capable of anterograde conduction who develop AF, conduction to the ventricle often occurs through a combination of the normal conduction pathway (via the AV node) and the AP. However, because most APs have a shorter refractory period than the AV node, the ventricular rate can be more rapid if AV conduction occurs preferentially via the AP. Hence, AV nodal blocking drugs (adenosine, verapamil, beta-blockers, and digoxin) should be avoided in patients with pre-excited AF, since blocking the AV node will promote conduction down the AP, lengthening AV node refractoriness, and may sometimes directly increase the rate of conduction over the AP. Myocardial contractility and systemic vascular resistance will also be

reduced, leading to a reflex increase in already elevated sympathetic tone that further shortens AP refractoriness.^{7–9}

The goals of acute drug therapy for pre-excited AF are prompt control of the ventricular response and, ideally, reversion to sinus rhythm. If the patient is unstable because of a rapid ventricular response, electrical cardioversion should be performed. For more stable patients, trials of intravenous medications can be performed cautiously. Treatment of pre-excited AF requires a parenteral drug with rapid onset of action that lengthens anterograde refractoriness and slows conduction in both the AV node/His-Purkinje system and the AP, such as ibutilide or procainamide.³

Our case illustrates an example of an iatrogenic malignant arrhythmia in a WPW patient presenting with a pre-excited AF that was neither promptly diagnosed nor properly treated.

Conclusion

Pre-excited AF is a differential diagnosis that ED doctors should bear in mind when treating patients with irregular wide complex tachycardias. In these patients, AV nodal blocking drugs will promote conduction down the AP, increasing the risk of developing VF, and should therefore be avoided. Acute treatment of pre-excited AF should aim for control of ventricular rate and, ideally, reversion to sinus rhythm. The preferred long-term treatment approach is catheter ablation.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Obeysekere MN, Leong-Sit P, Massel D, et al. Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a meta-analysis. *Circulation*. 2012;125:2308–15.
2. De Ponti R, Marazzi R, Doni LA, et al. Invasive electrophysiological evaluation and ablation in patients with asymptomatic ventricular pre-excitation persistent at exercise stress test. *Europace*. 2015;17:946–52.
3. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the management of adult patients with supraventricular tachycardia – a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practise Guidelines and the Heart Rhythm Society Society. *Circulation*. 2016;133:e506–74.
4. Pediatric and Congenital Electrophysiology Society (PACES), Heart Rhythm Society (HRS), American College of Cardiology Foundation (ACCF), et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). *Heart Rhythm*. 2012;9:1006.
5. Pappone C, Santinelli V, Rosanio S, et al. Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern. *J Am Coll Cardiol*. 2003;41:239–44.
6. Pappone C, Vicidomin G, Mangusto F, et al. Risk of malignant arrhythmias in initially symptomatic patients with Wolff-Parkinson-White syndrome – results of a prospective long-term electrophysiological follow-up study. *Circulation*. 2012;125:661–8.
7. Gulamhusein S, Ko P, Carruthers SG, et al. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. *Circulation*. 1982;65:348.
8. Simonian SM, Lotfipour S, Wall C, et al. Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation. *Intern Emerg Med*. 2010;5:421.
9. Sellers TD Jr, Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. *Circulation*. 1977;56:260.